GH Research (NASDAQ:GHRS) Stock Price Down 6.9% After Analyst Downgrade

GH Research logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • GH Research shares fell 6.9% after HC Wainwright cut its price target from $65 to $55, while maintaining a Buy rating.
  • Analyst sentiment remains broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $43.45; 10 analysts rate it Buy, one Hold, and one Sell.
  • The company reported a quarterly loss of $0.18 per share, beating analysts’ estimate of a $0.31 loss. Trading volume was 15,632 shares, 95% below its average session volume.
  • MarketBeat previews the top five stocks to own by December 1st.

GH Research PLC (NASDAQ:GHRS - Get Free Report) fell 6.9% during trading on Tuesday after HC Wainwright lowered their price target on the stock from $65.00 to $55.00. HC Wainwright currently has a buy rating on the stock. GH Research traded as low as $17.97 and last traded at $17.7870. 15,632 shares were traded during trading, a decline of 95% from the average session volume of 305,740 shares. The stock had previously closed at $19.10.

GHRS has been the topic of several other reports. New Street Research set a $65.00 price target on shares of GH Research in a report on Monday, August 10th. Guggenheim upped their price objective on shares of GH Research from $34.00 to $40.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Zacks Research raised shares of GH Research from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 13th. Wells Fargo & Company started coverage on shares of GH Research in a research report on Monday, July 27th. They issued an "overweight" rating and a $44.00 target price on the stock. Finally, Stifel Nicolaus set a $38.00 target price on shares of GH Research in a research report on Friday. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, GH Research currently has a consensus rating of "Moderate Buy" and an average target price of $43.45.

Check Out Our Latest Analysis on GH Research

Institutional Trading of GH Research

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Braidwell LP acquired a new stake in GH Research during the 2nd quarter worth approximately $5,571,000. Troluce Capital Advisors LLC grew its holdings in GH Research by 165.4% during the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company's stock worth $13,926,000 after acquiring an additional 617,260 shares during the last quarter. Squarepoint Ops LLC acquired a new position in GH Research in the 2nd quarter valued at approximately $495,000. Renaissance Technologies LLC acquired a new position in GH Research in the 1st quarter valued at approximately $290,000. Finally, Bellevue Group AG acquired a new position in GH Research in the 3rd quarter valued at approximately $109,000. 56.90% of the stock is currently owned by institutional investors.

GH Research Stock Down 5.5%

The company's 50 day moving average price is $22.11 and its 200-day moving average price is $21.65. The stock has a market cap of $1.22 billion, a P/E ratio of -18.66 and a beta of 1.31.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.13. Equities research analysts anticipate that GH Research PLC will post -1.20 earnings per share for the current year.

GH Research Company Profile

(Get Free Report)

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GH Research Right Now?

Before you consider GH Research, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.

While GH Research currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines